MedTrace Logo

Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)

NCT04295850 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2025-12-02

No results posted yet for this study

Summary

This proposal has three aims to characterize the relationship between aspirin therapy, platelet function response, and prevention of hypertensive disorders of pregnancy (HDP) through a prospective, cohort study using pharmacokinetics, pharmacodynamics, pharmacogenomics and bioinformatics. The results of this proposal will provide necessary data for prospective study on individualized aspirin dose adjustment for prevention of HDP.

Conditions

Interventions

DRUG

Aspirin 81 mg

Aspirin 81mg daily PO

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • March of Dimes

    collaborator OTHER

  • Thomas Jefferson University

    lead OTHER

Eligibility

Min Age
10 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-21
Primary Completion
2022-11-18
Completion
2023-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04295850 on ClinicalTrials.gov